Melatonin May Curtail the Metabolic Syndrome: Studies on Initial and Fully Established Fructose-Induced Metabolic Syndrome in Rats

To examine the effect of melatonin given to rats simultaneously with fructose on initial and fully developed metabolic syndrome, male Wistar rats had free access to chow and 5% or 10% fructose drinking solution for 8 weeks. As compared to controls, systolic blood pressure augmented significantly under both treatments whereas excessive body weight was seen in rats receiving the 10% fructose only. Rats drinking 5% fructose showed a greater tolerance to a glucose load while rats having access to a 10% fructose drinking solution exhibited the expected impaired glucose tolerance found in the metabolic syndrome. Circulating triglyceride and low density lipoproteins-cholesterol (LDL-c) concentration augmented significantly in rats showing a fully developed metabolic syndrome only, while high blood cholesterol levels were found at both stages examined. Melatonin (25 μg/mL drinking solution) counteracted the changes in body weight and systolic blood pressure found in rats administered with fructose. Melatonin decreased the abnormal hyperglycemia seen after a glucose load in 10% fructose-treated rats but it did not modify the greater tolerance to glucose observed in animals drinking 5% fructose. Melatonin also counteracted the changes in plasma LDL-c, triglyceride and cholesterol levels and decreased plasma uric acid levels. The results underline a possible therapeutical role of melatonin in the metabolic syndrome, both at initial and established phases.

[1]  E. D. du Toit,et al.  Melatonin and the metabolic syndrome: a tool for effective therapy in obesity‐associated abnormalities? , 2012, Acta physiologica.

[2]  K. Ohashi,et al.  Melatonin improves metabolic syndrome induced by high fructose intake in rats , 2012, Journal of pineal research.

[3]  B. Cummings,et al.  Fructose‐Fed Rhesus Monkeys: A Nonhuman Primate Model of Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes , 2011, Clinical and translational science.

[4]  L. Fuentes-Broto,et al.  Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[5]  D. Cardinali,et al.  Melatonin—A pleiotropic, orchestrating regulator molecule , 2011, Progress in Neurobiology.

[6]  D. Cardinali,et al.  Melatonin and the Metabolic Syndrome: Physiopathologic and Therapeutical Implications , 2011, Neuroendocrinology.

[7]  D. Cardinali,et al.  Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat–fed rats , 2010, Journal of pineal research.

[8]  L. Tappy,et al.  Fructose and metabolic diseases: new findings, new questions. , 2010, Nutrition.

[9]  D. Dijk,et al.  British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders , 2010, Journal of psychopharmacology.

[10]  G. Oxenkrug,et al.  Ramelteon attenuates age‐associated hypertension and weight gain in spontaneously hypertensive rats , 2010, Annals of the New York Academy of Sciences.

[11]  Kathryn Moynihan Ramsey,et al.  Circadian Rhythms and Metabolic Syndrome: From Experimental Genetics to Human Disease , 2010, Circulation research.

[12]  C. Sartori,et al.  Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. , 2009, Endocrinology.

[13]  A. Avenell,et al.  Systematic Review of Long-term Lifestyle Interventions to Prevent Weight Gain and Morbidity in Adults. Authors: , 2009 .

[14]  J. McNeill,et al.  The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension , 2009, Molecular and Cellular Biochemistry.

[15]  Zhenyu Guo,et al.  NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. , 2009, Pharmacological research.

[16]  Marta Garaulet,et al.  Chronobiology, genetics and metabolic syndrome , 2009, Current opinion in lipidology.

[17]  F. Scheer,et al.  Adverse metabolic and cardiovascular consequences of circadian misalignment , 2009, Proceedings of the National Academy of Sciences.

[18]  E. Grossman,et al.  The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. , 2008, American journal of hypertension.

[19]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  C. Alonso-González,et al.  Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. , 2007, Maturitas.

[21]  H. Dralle,et al.  Melatonin and type 2 diabetes – a possible link? * , 2007, Journal of pineal research.

[22]  M. Raskind,et al.  Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats , 2007, Neuropsychopharmacology.

[23]  Marwa A. Ahmed,et al.  Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model , 2006, International journal of experimental pathology.

[24]  D. Rasmussen,et al.  Melatonin effect on rat body weight regulation in response to high-fat diet at middle age , 2003, Endocrine.

[25]  B. Guardiola-Lemaitre Agonistes et antagonistes des récepteurs mélatoninergiques : perspectives thérapeutiques , 2007 .

[26]  B. Guardiola‐Lemaître [Melatoninergic receptor agonists and antagonists: therapeutic perspectives]. , 2007, Journal de la Societe de biologie.

[27]  Y. Sharabi,et al.  Melatonin reduces night blood pressure in patients with nocturnal hypertension. , 2006, The American journal of medicine.

[28]  Takahiko Nakagawa,et al.  A causal role for uric acid in fructose-induced metabolic syndrome. , 2006, American journal of physiology. Renal physiology.

[29]  K. Shimamoto,et al.  Mechanisms of Insulin Resistance in Hypertensive Rats , 2006, Clinical and experimental hypertension.

[30]  M. Kanter,et al.  Depression of glucose levels and partial restoration of pancreatic β-cell damage by melatonin in streptozotocin-induced diabetic rats , 2006, Archives of Toxicology.

[31]  A. Cagnacci,et al.  Prolonged melatonin administration decreases nocturnal blood pressure in women. , 2005, American journal of hypertension.

[32]  S. Daniels,et al.  Blood pressure‐lowering effect of melatonin in type 1 diabetes , 2004, Journal of pineal research.

[33]  F. Scheer,et al.  Daily Nighttime Melatonin Reduces Blood Pressure in Male Patients With Essential Hypertension , 2004, Hypertension.

[34]  P. Renard,et al.  Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. , 2003, Endocrinology.

[35]  R. Sato,et al.  Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats , 2003, Journal of pineal research.

[36]  D. Cardinali,et al.  Melatonin increases oestradiol‐induced bone formation in ovariectomized rats , 2003, Journal of pineal research.

[37]  N. Roglans,et al.  Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. , 2002, The Journal of pharmacology and experimental therapeutics.

[38]  C. K. Song,et al.  Seasonal Changes in Adiposity: the Roles of the Photoperiod, Melatonin and Other Hormones, and Sympathetic Nervous System , 2002, Experimental biology and medicine.

[39]  S. Nakagawa,et al.  Long‐term melatonin administration reduces hyperinsulinemia and improves the altered fatty‐acid compositions in type 2 diabetic rats via the restoration of Δ‐5 desaturase activity , 2002, Journal of pineal research.

[40]  G. Lewis,et al.  Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats. , 1997, Journal of lipid research.

[41]  J. McNeill,et al.  Fructose-induced hypertension in rats is concentration- and duration-dependent. , 1995, Journal of pharmacological and toxicological methods.